Shanghai Shenqi Pharmaceutical Investment Management Co., Ltd. Class A

Shanghai Shenqi Pharmaceutical Investment Management Co., Ltd. Class A

5.86
CNY
-0.22
(-3.62%)
0.03EPS
531.44P/E
4.37BMarket Cap

Total Valuation

CNY

As of September 30, 2026, Shanghai Shenqi Pharmaceutical Investment Management Co., Ltd. Class A carries a market capitalization of 4.37B, placing it among publicly traded companies globally. Its enterprise value stands at 3.76B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap4.37B
Enterprise Value3.76B

Share Statistics

As of September 30, 2026, Shanghai Shenqi Pharmaceutical Investment Management Co., Ltd. Class A has 534.07M shares outstanding.

Shares Outstanding534.07M

Valuation Ratios

As of September 30, 2026, Shanghai Shenqi Pharmaceutical Investment Management Co., Ltd. Class A trades at a trailing price-to-earnings ratio of 531.44. The price-to-sales ratio is 2.55, and the price-to-book ratio stands at 1.91.

PE Ratio531.44
PS Ratio2.55
PB Ratio1.91
P/TBV Ratio2.23

Enterprise Valuation

As of September 30, 2026, Shanghai Shenqi Pharmaceutical Investment Management Co., Ltd. Class A trades at an EV/EBITDA multiple of 72.45 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 2.09 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 72.45 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 3.76B versus a market cap of 4.37B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales2.09
EV / EBITDA72.45
EV / EBIT72.45

Financial Position

As of September 30, 2026, Shanghai Shenqi Pharmaceutical Investment Management Co., Ltd. Class A maintains a current ratio of 2.91, meaning it holds 2.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 2.62, indicating elevated leverage, while an interest coverage ratio of 6.60 demonstrates adequate ability to service its debt obligations.

Current Ratio2.91
Quick Ratio1.47
Debt / Equity2.62
Debt / EBITDA1.20
Interest Coverage6.60

Financial Efficiency

CNY

Over the twelve months ended September 30, 2026, Shanghai Shenqi Pharmaceutical Investment Management Co., Ltd. Class A posted a return on equity (ROE) of 0.38, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 0.66 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 0.29, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 0.17, useful for judging operating efficiency across full business cycles. The company generates approximately 1.51M in revenue per employee across its workforce of 1,196.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 4.89 indicates how many times Shanghai Shenqi Pharmaceutical Investment Management Co., Ltd. Class A sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Equity (ROE)0.38
Return on Assets (ROA)0.29
Return on Invested Capital (ROIC)0.66
Return on Capital Employed (ROCE)0.17
Revenue Per Employee1.51M
Employee Count1,196.00
Inventory Turnover4.89

Taxes

CNY

Over the twelve months ended September 30, 2026, Shanghai Shenqi Pharmaceutical Investment Management Co., Ltd. Class A recorded 33.25M in income tax expense. That works out to an effective tax rate of 67.99, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 48.91M, leaving 8.65M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

Income Tax33.25M
Effective Tax Rate67.99

Stock Price Statistics

CNY

As of the close on November 17, 2026, Shanghai Shenqi Pharmaceutical Investment Management Co., Ltd. Class A's stock has declined approximately 14.95% over the past 52 weeks. The 50-day moving average sits at 7.73, while the 200-day moving average is 6.37.

52-Week Price Change-14.95%
50-Day Moving Average7.73
200-Day Moving Average6.37

Income Statement

CNY

Over the twelve months ended September 30, 2026, Shanghai Shenqi Pharmaceutical Investment Management Co., Ltd. Class A generated 1.80B in revenue and converted that into 8.65M in net income, yielding earnings per share of 0.03. EBITDA reached 51.95M, while operating income came in at 96.31M.

Revenue1.80B
Gross Profit777.24M
Operating Income96.31M
Pretax Income48.91M
Net Income8.65M
EBITDA51.95M
EBIT51.95M
Earnings Per Share (EPS)0.03

Balance Sheet

CNY

As of September 30, 2026, Shanghai Shenqi Pharmaceutical Investment Management Co., Ltd. Class A holds 755.95M in cash and equivalents against 62.20M in total debt, resulting in a net debt position of -508.91M. Total book value stands at 2.29B, with working capital of 981.15M providing operational flexibility.

Cash & Cash Equivalents755.95M
Total Debt62.20M
Net Debt-508.91M
Equity (Book Value)2.29B
Book Value Per Share4.30
Working Capital981.15M

Cash Flow

CNY

These figures cover the twelve months ended September 30, 2026.

Capital Expenditures-18.14M

Margins

Over the twelve months ended September 30, 2026, Shanghai Shenqi Pharmaceutical Investment Management Co., Ltd. Class A posted a gross margin of 43.09, reflecting its pricing power and cost economics. The operating margin of 5.34 and net profit margin of 0.48 provide insight into operational efficiency.

Gross Margin43.09
Operating Margin5.34
Pretax Margin2.71
Profit Margin0.48
EBITDA Margin2.88

Dividends & Yields

CNY

Over the twelve months ended September 30, 2026, Shanghai Shenqi Pharmaceutical Investment Management Co., Ltd. Class A paid dividends of 0.07 per share. The dividend payout ratio of 183.40 exceeds 100%, meaning the company is distributing more than it earns and funding the dividend from cash reserves, asset sales, or borrowing, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield reaches 3.57, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Shanghai Shenqi Pharmaceutical Investment Management Co., Ltd. Class A shareholders.

Dividend Per Share0.07
Payout Ratio183.40
Shareholder Yield3.57

Stock Splits

Shanghai Shenqi Pharmaceutical Investment Management Co., Ltd. Class A's most recent stock split took place on July 6, 2015 with a 5:6 split ratio.

Last Split Date7/6/2015
Split Ratio5:6

Scores

As of September 30, 2026, Shanghai Shenqi Pharmaceutical Investment Management Co., Ltd. Class A has an Altman Z-Score of 6.49, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score6.49